scispace - formally typeset
Journal ArticleDOI

Molecular genetics of lung cancer in people who have never smoked.

TLDR
Patients with lung cancer who have never smoked are more likely to have mutations in epidermal growth factor receptor (EGFR) tyrosine kinase and have better response to its inhibitors than do patients with tobacco-associated lung cancer.
Abstract
Lung cancer is a major cause of cancer-related mortality in the USA, and tobacco smoke is the major risk factor for this disease. However, many patients with lung cancer have never smoked (never smokers). Patients with lung cancer who have never smoked are more likely to have mutations in epidermal growth factor receptor (EGFR) tyrosine kinase and have better response to its inhibitors than do patients with tobacco-associated lung cancer. Furthermore, the prevalences of mutations in KRAS and P53 differ for patients with lung cancer who have never smoked and those with tobacco-associated lung cancer. Genetic mutations seem to be more common in patients with tobacco-associated lung cancer than in never smokers. Current evidence indicates that the two types of lung cancer are biologically distinct. Here, we review published studies of the molecular genetics of lung cancer in never smokers and identify the specific differences from tobacco-associated lung cancer.

read more

Citations
More filters

Lung Cancer in Never Smokers - Different Disease

Gazdar
TL;DR: Current knowledge of lung cancers arising in never smokers versus smokers is summarized, suggesting that they are separate entities.
Journal ArticleDOI

Lung cancer in never smokers--a review.

TL;DR: Current clinical and molecular aspects of LCINS are reviewed, including the type of molecular mutation in p53 or KRAS varies with smoking status, which is a strong argument in favour of separate genetic paths to cancer for ever smokers and never smokers.
Journal ArticleDOI

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

TL;DR: A highly sensitive multiplexed clinical assay that performs very well with nucleic acid derived from formalin fixation and paraffin embedding tissue, and tests for 120 previously described mutations in 13 cancer genes, establishes a platform for real‐time targeted genotyping that can be widely adopted.

iArc monogrAphs on the evAluAtion oF cArcinogenic risks to humAns

TL;DR: PReVIously ClAssIfIed by IARC As “CARCInogenIC to humAns (gRoup 1)” And wAs deVeloped by sIx sepARAte woRkIng gRoups: phARmACeutICAls; bIologICAl Agents; ARsenIC, metAls, fIbRes, And dusts; RAdIAtIon; peRsonAl
References
More filters
Journal ArticleDOI

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Journal ArticleDOI

Cancer statistics, 2006.

TL;DR: The American Cancer Society estimated the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute and mortality data from National Center for Health Statistics as discussed by the authors.
Related Papers (5)